Project Grant R01AI184380
Award Date
7/10/25
Completion Date
6/30/30
Dollars Obligated
$525K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $134,269 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research led by the Trustees of Tufts College, doing business as Tufts University School of Medicine, to characterize the structure and antigenic properties of the human cytomegalovirus (HCMV) glycoprotein B (GB) in its prefusion state. The research aims to identify and isolate novel...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
This Project Grant award of $666,567 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Los Angeles (UCLA) to investigate the transcriptional regulation of human natural killer (NK) cell function in response to viral infections, such as human cytomegalovirus (HCMV). The key objectives are to determine the mechanisms by which the transcription factor MEF2C regulates NK cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $365,608 to Duke University to conduct research on human cytomegalovirus (HCMV) infection at the maternal-fetal interface. The primary objectives are to identify factors that restrict HCMV replication in trophoblasts, the predominant cell type in the placenta, and to define the impacts of HCMV-induced expression of the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $426,939 to Virginia Commonwealth University to conduct research on the modulation of cytomegalovirus (CMV) replication by the viral "temperance factor" RL13. The research aims to determine the mechanism by which RL13 restricts CMV replication and how the immediate early 2 (IE2) protein isoforms impact RL13 activity. The findings...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $682,879 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical College of Wisconsin, Inc. to conduct research on the impact of human cytomegalovirus (HCMV) infection on the development of human neural tissues. The 5-year project aims to: 1) define the transcriptional and cellular disruptions to developing human neural cells caused by HCMV infection, 2) determine the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,135,986 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to investigate strategies for mitigating cytomegalovirus (CMV) reactivation in kidney transplant recipients. The research aims to identify cellular and molecular targets, specifically related to endoplasmic reticulum stress and mitochondrial dysfunction in renal endothelial cells, that can be...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $290,132 to the University of Wisconsin - Madison to study how the cellular protein SLBP promotes the infectivity of human cytomegalovirus (HCMV). The goal is to identify and characterize the novel, pro-viral function of SLBP during HCMV infection. The research aims to determine the specific function of SLBP required to increase HCMV...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on manipulating the DNA damage response and proteome on viral genomes during herpes simplex virus (HSV) infection. The $651,832 award, with a project period from November 2024 to October 2029, will enable researchers at The Children's Hospital of Philadelphia to conduct a multi-modal proteomic...